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Abstract
Background: The induction of sterile immunity and long lasting protection against malaria has been effectively
achieved by immunization with sporozoites attenuated by gamma-irradiation or through deletion of genes. For
mice immunized with radiation attenuated sporozoites (RAS) it has been shown that intrahepatic effector memory
CD8
+ T cells are critical for protection. Recent studies have shown that immunization with genetically attenuated
parasites (GAP) in mice is also conferred by liver effector memory CD8
+ T cells.
Findings: In this study we analysed effector memory cell responses after immunization of GAP that lack the P52
protein. We demonstrate that immunization with p52
-GAP sporozoites also results in a strong increase of effector
memory CD8
+ T cells, even 6 months after immunization, whereas no specific CD4
+ effector T cells response could
be detected. In addition, we show that the increase of effector memory CD8
+ T cells is specific for the liver and
not for the spleen or lymph nodes.
Conclusions: These results indicate that immunization of mice with P. berghei p52
-GAP results in immune
responses that are comparable to those induced by RAS or GAP lacking expression of UIS3 or UIS4, with an
important role implicated for intrahepatic effector memory CD8
+ T cells. The knowledge of the mediators of
protective immunity after immunization with different GAP is important for the further development of vaccines
consisting of genetically attenuated sporozoites.
Findings
Immunization studies using live radiation-attenuated spor-
ozoites (RAS) demonstrated full protection against subse-
quent challenge with infectious plasmodial sporozoites in
mice, in non-human primates, and in humans [reviewed
in [1]]. This protection is now known to be mediated by
complex mechanisms involving both antibody and T cell
responses [reviewed in [2]]. The long-lasting RAS-induced
sterile immunity in mice is characterized by the establish-
ment of a CD44
highCD45RB
lowCD62L
low subset of
memory CD8
+ T cells (but not of CD4
+ Tc e l l s )i nt h e
liver but not in the spleen [3,4]. Recently, it has been
shown that genetically attenuated parasites (GAP), lacking
conserved sporozoite-specific genes that are important for
development inside the hepatocyte, can induce partial or
complete protective immunity in rodent models of malaria
[5-10]. We have previously characterized the immuniza-
tion potential of P. berghei p52
-GAP [7,9] that do not
express the sporozoite-specific microneme protein P52
(PBANKA_100220; also known as P36p) [11]. Here, we
sought to quantify memory lymphocytes, elicited by
immunizations with p52
-GAP, which may play a role in
maintenance in the long-lasting immunity conferred by
these attenuated parasites. We show that the long-lasting
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sence and persistence of an expanded population of CD8
+
effector memory T cells found only in the liver.
High levels of CD8
+ effector memory T cells are
maintained for up to 6 months exclusively in the livers of
p52
- GAP-immunized mice
We have recently shown that BALB/c mice immunized
with p52
-GAP are protected when challenged with infec-
tious P. berghei sporozoites 6 months later, without
requiring additional boosts [9]. Immunological memory
in RAS-immunized C57BL6 mice is associated with the
establishment of effector memory CD8
+ T cells found in
the liver, but not in the spleen [3,4]. Similar results were
observed for P. berghei double knockout uis3
-/uis4
-GAP
in C57BL6 mice [12] and P. yoelii uis4
-GAP in BALB/c
mice [13]. To determine whether similar cells are elicited
by p52
-GAP, we quantified effector memory CD8
+
T cells in different organs of GAP-immunized BALB/c
mice (this study was carried out in strict accordance with
the recommendations of both the Animal Experiment
Committees governed by section 18 of the Experiments
on Animals Act and registered by the Dutch Inspectorate
for Health, Protection and Veterinary Public Health
(Ministry of Health, Welfare and Sport), and the Portu-
guese official Veterinary Directorate, which complies
with the Portuguese Law (Portaria 1005/92); the Dutch
and Portuguese Experiments on Animal Act strictly com-
ply with the European Guideline 86/609/EEC and follow
the Federation of European Laboratory Animal Science
Associations guidelines and recommendations concern-
ing laboratory animal welfare. In The Netherlands, all
animal experiments were approved by the Animal
Experiments Committee of the LUMC (ADEC). In Portu-
gal, all animal experiments were approved by the Portu-
guese official veterinary department for welfare licensing
and the Instituto Gulbenkian de Ciencia Animal Ethics
Committee). Six-week old female BALB/c mice (Instituto
Gulbenkian de Ciência, Oeiras, Portugal) were immu-
nized intravenously with 50,000 p52
- P. berghei sporo-
zoites (ANKA strain, expressing GFP [7], obtained by
hand dissection of infected mosquitoes [14]). p52
-GAP-
immunized mice were sacrificed at different times post-
immunization (10 days, 1 and 6 months) to collect livers,
spleens and lymph nodes, from which non- parenchymal
cells were isolated as described previously [3,4,15]. In
parallel, mice immunized identically were challenged
with 10,000 infectious P. berghei ANKA sporozoites, con-
firming full protection against subsequent infection, at all
the time points (10 days, 1 and 6 months) memory cells
were analysed (data not shown).
For fluorescence-associated cell sorting (FACS) ana-
lyses, lymphocytes were incubated with fluorochrome-
conjugated antibodies for 15 minutes on ice, washed and
resuspended for FACS acquisition on a flow cytometer
FACSCalibur (BD Biosciences). For each group of mice,
a representative pool of cells was analyzed. Memory
CD8
+ T cells were quantified using the combination of
CD8-PerCP-Cy5/CD44-APC/CD62L-FITC antibodies
(Pharmingen).
The numbers of CD8
+ effector memory T cell
(CD44
highCD62L
low) increased nearly three-fold in the
livers of immunized versus naïve mice when measured
10 days post-immunization (Figure 1A, B). At 1 month
post-immunization, the CD8
+CD44
highCD62L
low cell
population was still ~2.5-fold higher in the livers of
immunized versus naïve mice, and remained at the
same level 6 months post-immunization (Figure 1B).
In the spleens of p52
-GAP-immunized mice, only a
modest increase (~1.5 fold) in the number of CD8
+
effector memory T cells was observed 10 days post-
immunization (Figure 1B), returning to basal levels 1
month post-immunization (Figure 1B).
The initial site of induction of memory CD8
+ T cells
found in the liver after immunization with attenuated
sporozoites is unclear. It has been suggested that it occurs
in the liver itself or that such cells are induced in draining
lymph nodes, from where they migrate to the liver follow-
ing sporozoite challenge [16]. We therefore quantified
effector memory CD8
+ T cells in the lymph nodes of non-
immunized and p52
-GAP-immunized mice, 10 days post-
immunization. No increase in effector memory CD8
+
T cells was observed in the immunized mice (Figure 1B),
suggesting that the liver rather than lymph nodes is prob-
ably the principal site of induction of memory T cells fol-
lowing p52
-GAP immunization.
CD4
+ effector memory T cells are not induced after
immunization with p52
- sporozoites.
Effector memory CD4
+ T cells were quantified by FACS as
described for CD8
+ T cells, with the following conjugated
antibodies: CD4+ PE/CD44-APC/CD62L-FITC (Pharmin-
gen). In contrast to effector memory CD8
+ T cells, there
was no marked increase in the number of CD4
+ effector
memory T cells (defined as CD44
highCD62L
low) in any of
the organs examined after immunization (Figure 1C)
Protection against chronic infections like malaria
requires robust responses by the lymphocyte arm of the
adaptive immune system, and relies on induction and
maintenance of immunological memory. In our studies
with p52
-GAP, maintenance of protective immune
responses after the first immunization in BALB/c mice
required no additional boosting by challenge infections,
for example, and mice remained fully protected for up
to 6 months [9]. We found that maintaining protective
immunity beyond this 6 months period, however, does
require de novo antigen presentation via, for example,
additional challenge infection with sporozoites. Renewed
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Page 2 of 5Figure 1 Effector memory CD8
+ and CD4
+ T cells in naïve and p52
- immunized mice. For each analysed organ, cell populations were
defined as either CD8
+ or CD4
+ T cells, and subpopulations of effector memory cells within those populations were defined as
CD44
highCD62L
low. (A) Flow cytometry analysis of CD8
+CD44
highCD62L
low memory T cells in the liver of naïve (left panels) or immunized (Imm,
right panels) mice 10 days after immunization with p52
- sporozoites. Although the levels of CD8
+ T cells are similar in both naïve and Imm mice
(8.9% versus 12.4%, upper panels), the percentage of CD8
+ effector memory cells is much higher in Imm than in naïve mice (61.3% versus 19.8%,
lower panels). Values refer to percentage of cells in the respective quadrant. (B) Relative proportion (fold increase) of CD8
+ effector memory T
cells in naïve and immunized mice (n = 3 per group) in liver (Lv), spleen (Sp) and lymph nodes (LN) at different time points after immunization
(A.I.). Effector memory CD8+ T cells were quantified as shown in (A) and results are displayed as fold increase in immunized mice over naive
mice. (C) Relative proportion of CD4
+CD44
highCD62L
low (effector) memory T cells in the same immunized and naïve mice as shown in (B). These
cells were quantified as described in (B) from mice at 10 days after immunization. FACS analyses were performed on pooled cells from three
animals within the same group, and 100,000 to 200,000 events per each phenotype studied were analysed.
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full protective immune responses over prolonged peri-
ods after the initial GAP immunization. RAS-immunized
mice indeed require the presence of antigen to maintain
protective immunity [17], through re-stimulation of
intrahepatic memory T cells [4]. Such re-stimulation
can comprise challenge infection with wild-type para-
sites or may result from the presence of persisting anti-
gen [reviewed in 18]. Persistence of plasmodial antigen
can derive from either residual parasites in the liver or
in the form of circulating parasite proteins or peptide-
MHC complexes. It has been suggested that apoptotic
infected hepatocytes could provide plasmodial antigens
to professional APC [reviewed in [2,18]]. These would
consequently migrate from the liver and act like an anti-
gen depot, explaining why mice treated with drugs to
clear intrahepatic parasite load can still be protected
[17-19]. Also, antigenic load supplied by the different
immunization strategies appears to be a critical factor; a
high dose of antigen would mean a larger antigen depot,
therefore inducing a more long-lasting protection
[reviewed in [2,18]]. We found that, in p52
-GAP-immu-
nized mice, the population of CD8
+ effector memory T
cells in the liver, at 10 days post-immunization, is
greater than that observed at later time points, most
probably indicating depletion or exhaustion of the anti-
gen depot. A very recent work states that antigen persis-
tence occurs in live- and RAS- immunized mice even
upon drug treatment to clear the liver parasites [17]. In
these conditions, the development of a CD8
+ T cell
response was also efficient, but not when heat-killed
sporozoites were used, indicating that only metabolically
active parasites can act as source of antigen. Therefore,
as seems to be the case for RAS-induced protection
[17-19], p52
-GAP-induced protective immune responses
appear to depend on continuous antigen presentation
provided by a persisting antigen depot. In the study pre-
sented here, perhaps not unexpectedly, we observed
similarities between the immune responses induced by
GAP and RAS. As already reported for RAS [3,4], P.
berghei uis3
-/uis4
- GAP [12] and P. yoelii uis4
-GAP [13],
p52
-GAP immunization elicits effector memory CD8
+ T
cells solely in the liver and not in the spleen or lymph
nodes, indicating that organ-specific responses in the
liver are probably crucial for the establishment of long-
lasting protection in this system. Although priming of
CD8+ T cells against plasmodial sporozoites’ antigens
occurs also in skin-draining lymph nodes, hepatocytes
can also present plasmodial antigens via MHC classe I
[ r e v i e w e di n[ 1 8 ] ] .T h el a t e rw o u l db em o r ee f f i c i e n t ,
since a broader range of antigens (from both sporozoite
and liver developing plasmodial schizont) would be pre-
sented to the immune system. Also, the vast majority of
sporozoites reach the liver shortly after inoculation,
strengthening the hypothesis that most of the induction
of immune cells occurs in the liver. Regarding effector
memory CD4
+ T cells, their numbers remain unchanged
following p52
-GAP immunization, as has been found in
RAS-immunized mice [3], implying no major role for
these cells in the protection conferred by attenuated
parasites. Our results, together with those of others
[3,4,12,13,18,20], strongly emphasize the role of the
liver, and particularly of intrahepatic effector memory
CD8
+ T cells, in the maintenance of the sterile immu-
nity conferred by attenuated plasmodial sporozoites.
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